No deaths or serious adverse events were reported at any time point.

Objective: Errors in community medication histories increase the risk of adverse events.

Results: No patient had a treatment-emergent serious adverse events at day 30.

No adverse events or other health problems were observed during the study.

Thirty cases of serious adverse events involved medication prescribing, dispensing or administration.

Results: No serious adverse events were observed following application of IL-12-releasing smDC.

Results: Twenty-three patients underwent PDN, with no procedure-related serious adverse events reported.

There was no difference in serious adverse events according to treatment category.

Acura said there were no serious adverse events reported in the trial.

No serious or major bleeding-related adverse events were reported during either study.

However, these adverse events were controlled and no treatment-related deaths were observed.

The MEC regimen exhibited a good response rate with tolerable adverse events.

The occurrence of serious adverse events was not significantly different between arms.

Primary safety end points were adverse events after discharge and hospital readmission.

Incidence and severity of common adverse events were consistent with previous reports.

Secondary safety endpoints included serious adverse events and death at 30 days.